1684年（清康熙二十三年），時任太醫院吏目的樂顯揚因醫術高超、醫德高尚，被康熙皇帝誥封為“登仕佐郎”

In 1684, the 23rd Qing Kangxi reign, Mr. Yue Xianyang, the senior physician and instruction at the Imperial Hospital, was officially conferred on him a ninth-grade official rank by Emperor Kangxi of the Qing dynasty for his excellent medical skills and professional ethics.

1702年（清康熙四十一年），樂鳳鳴在北京前門外大柵欄開設同仁堂藥鋪

1706年（清康熙四十五年），樂鳳鳴編寫完成《同仁堂樂氏世代祖傳丸散膏丹下料配方》（簡稱《同仁堂傳統配本》）和《同仁堂虔修諸門應癥丸散膏丹總目》（簡稱《同仁堂藥目》），為同仁堂制作藥品建立起嚴格的選方、用藥、配比和工藝規范

In 1706, the 45th Qing Kangxi reign, Mr. Yue Fengming completed TRT Traditional Medicine Matching based on the herbal medicine recipes in the forms of pill, pulvis, emplastrum and unguentum, and pellet handed down from the founders from one generation to another, and TRT Materia Medica, which caters to various indication also in the similar forms. As a whole, these two great medical works mandate such norms for Tongrentang as strict selection of prescriptions, application, proportioning, and process.

1723年（清雍正元年），同仁堂開始為清宮供御藥，歷經雍正、乾隆、嘉慶、道光、咸豐、同治、光緒、宣統八代皇帝，長達188年

In 1723, the 1st Qing Yongzheng reign, Tongrentang initiated its medication supply to the Qing Imperial Palace, over the eight reigns , for 188 years.

1949年，新中國成立使同仁堂獲得了新生

In 1949, the founding of the People’s Republic of China gave Tongrentang a new life.

1953年，同仁堂研制生產了中國第一批中藥片劑，結束了中藥只有丸、散、膏、丹傳統劑型的歷史，開創了先河

In 1953, Tongrentang developed the first batch of Traditional Chinese Medicine tablets, unprecedentedly ended the history of sole forms of pill, powder, ointment and pellet.

1955年，同仁堂經理樂松生在中南海受到毛澤東主席和周恩來總理的親切接見，被選為北京市人大代表，出任北京市副市長

In 1955, Mr. Yue Songsheng, the president of Tongrentang, was cordially received by Chairman Mao Zedong and Premier Zhou Enlai at Zhongnanhai. He was elected as a deputy of the Beijing People’s Congress and the vice mayor of Beijing municipality.

1989年，“同仁堂”商標成為中國“首批馬德里商標注冊”的國際商標

In 1989, the “Tongrentang” trademark was among the first Chinese trademark registered in Madrid.

1992年，中國北京同仁堂（集團）公司組建成立。

In 1992, China Beijing Tong Ren Tang Group Company was incorporated.

1993年，同仁堂獲得進出口經營權，在香港開設第一家門店，從此以香港為橋頭堡走向世界，目前已實現了在五大洲28個國家和地區的業務布局。

In 1993, Tongrentang set up its first pharmacy in Hong Kong, as a bridgehead to other parts of the world. So far Tongrentang’s overseas business has been distributed in 28 countries and regions.

1997年，北京同仁堂股份有限公司成立，并在上交所上市，標志著同仁堂在建立現代化企業制度的進程中邁出重要步伐。

In 1997, Beijing Tong Ren Tang Co., Ltd. was established, and was also listed on the Shanghai Stock Exchange.

2000年，北京同仁堂科技發展股份有限公司成立，并在香港創業板上市，為國內首家由A 股分拆上市的企業。

In 2000, Beijing Tong Ren Tang Technology Development Co., Ltd. was formed, and was also listed on the Hong Kong Growth Enterprises Market, as the first subsidiary A-share IPO enterprise.

2001年，中國北京同仁堂（集團）有限責任公司正式揭牌，標志著同仁堂實現了規范化的公司制改革

In 2001, China Beijing Tong Ren Tang (Group) Co., Ltd. unveiled the plaque officially, which signaled its achievement of the standardized corporate system reform.

2006年，中華人民共和國商務部認定中國北京同仁堂（集團）有限責任公司為首批“中華老字號”，“同仁堂中醫藥文化”入選首批國家級非物質文化遺產代表性名錄

In 2006, China Beijing Tong Ren Tang (Group) Co., Ltd. was assessed to be among the first batch of “China Time-honored Brand”, whereas “Tongrentang Traditional Chinese Medicine Culture” was inscribed on the representative first batch of the national intangible cultural heritages.

2013年，北京同仁堂國藥有限公司在香港創業板上市，成為同仁堂集團旗下第三家上市公司

In 2013, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. was listed on the Hong Kong Growth Enterprises Market, as the 3rd listed subsidiary company within Tongrentang Group.

2018年，同仁堂粹和康養天壇生活館開業，同仁堂正式進入養老領域，并向大健康產業進軍

In 2018, Tiantan Life Hall of TRT CUIHE Healthcare started its business, officially established as a pacesetter for elder-caring and greater health sector.

2019年，同仁堂公開聘請第三方權威機構開展戰略咨詢，標志著歷經350年風雨歷程的中華老字號企業，通過創新發展理念，以實際行動夯實黨建基石、質量基石、誠信基石，邁上高質量發展之路

In 2019, Tongrentang invited openly a third party competent institution for strategic consultancy. This marks that China Time-honored Brand business with a history of 350 years is pursuing for development of higher quality, through the vision of innovative development and actual enhancement of Party construction and credit-standing.